Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

Inclusion Criteria: * Age \> 18 * Histologically confirmed non-small cell cancer * One bone metastasis at least confirmed by image(X ray, CT or others) * NTX \> 50nM BCE/mM creatinine * Life expectancy \> 6 M * ECOG \<= 2 * Signed ICF Exclusion Criteria: * Women who are pregnant or in lactation * Patients with hyperostosis with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled * Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy * Severe co-morbidity of any type that may interfere with assessment of the patient for the study -